Neuronal survival deficits and metabolic abnormalities represent additional critical hallmarks of AD pathology, with the ENTPD2, DMXL2, and METTL7A genes emerging as key mediators of these processes—each governing distinct molecular pathways that collectively contribute to AD progression. This evidence concerns the gene DMXL2 and Alzheimer disease.